Skip to content

Heading to World Orphan Drug Congress in Boston? Learn how we can help accelerate access to patients in Europe. Talk to our team

Get the free whitepaper: Transitioning from open-label extensions to early access programs

Andrew Cummins

By Andrew Cummins

Director of Expanded Access Programs

Discover the strategic pathway to European market access for rare disease therapies

The European orphan drug market is expanding, offering biotech firms significant growth opportunities. Early access programs (EAPs) have become a key strategy for launching rare disease therapies, providing a faster route to market in Europe’s complex regulatory landscape.

Download our whitepaper to learn more about:

  • The shift from open-label extensions (OLEs) to EAPs
  • Key advantages of EAPs, including faster access and real-world data collection
  • How to navigate Europe’s regulatory challenges
  • Best practices for implementing EAPs successfully